Jason H Peragallo1. 1. Departments of Ophthalmology and Pediatrics, Emory University, Atlanta, Georgia, USA.
Abstract
PURPOSE OF REVIEW: To review the recent advances in understanding how primary brain tumors affect vision in children. RECENT FINDINGS: Children with primary brain tumors may have vision loss due to involvement of their afferent visual pathways or from papilledema. These vision deficits may go unrecognized until later in life, years after treatment of the primary lesion. Strabismus and cranial nerve palsies may occur as a result of brain tumors. Ophthalmologists can monitor and treat young children at risk for vision loss from amblyopia as a result of effects from their underlying lesion. Advances in imaging techniques have made it possible to quantify damage to the visual pathways with objective tests. SUMMARY: Systematic referrals for evaluation by an ophthalmologist should occur early in the course of treatment of primary brain tumors as these evaluations may improve visual outcomes and quality of life.
PURPOSE OF REVIEW: To review the recent advances in understanding how primary brain tumors affect vision in children. RECENT FINDINGS:Children with primary brain tumors may have vision loss due to involvement of their afferent visual pathways or from papilledema. These vision deficits may go unrecognized until later in life, years after treatment of the primary lesion. Strabismus and cranial nerve palsies may occur as a result of brain tumors. Ophthalmologists can monitor and treat young children at risk for vision loss from amblyopia as a result of effects from their underlying lesion. Advances in imaging techniques have made it possible to quantify damage to the visual pathways with objective tests. SUMMARY: Systematic referrals for evaluation by an ophthalmologist should occur early in the course of treatment of primary brain tumors as these evaluations may improve visual outcomes and quality of life.
Authors: Quinn T Ostrom; Haley Gittleman; Peter Liao; Toni Vecchione-Koval; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan Journal: Neuro Oncol Date: 2017-11-06 Impact factor: 12.300
Authors: Robert A Avery; Eugene I Hwang; Hiroshi Ishikawa; Maria T Acosta; Kelly A Hutcheson; Domiciano Santos; Dina J Zand; Lindsay B Kilburn; Kenneth N Rosenbaum; Brian R Rood; Joel S Schuman; Roger J Packer Journal: JAMA Ophthalmol Date: 2014-03 Impact factor: 7.389
Authors: Robert A Avery; Avital Cnaan; Joel S Schuman; Carmelina Trimboli-Heidler; Chieh-Li Chen; Roger J Packer; Hiroshi Ishikawa Journal: Am J Ophthalmol Date: 2015-07-29 Impact factor: 5.258
Authors: Myrthe A Nuijts; Inge Stegeman; Tom van Seeters; Marloes D Borst; Carlien A M Bennebroek; Dennis R Buis; Nicole C Naus; Giorgio L Porro; Michelle B van Egmond-Ebbeling; Elisabeth S M Voskuil-Kerkhof; JanWillem R Pott; Niels E Franke; Evelien de Vos-Kerkhof; Eelco W Hoving; Antoinette Y N Schouten-van Meeteren; Saskia M Imhof Journal: JAMA Ophthalmol Date: 2022-10-01 Impact factor: 8.253
Authors: Myrthe A Nuijts; Inge Stegeman; Giorgio L Porro; Josje C Duvekot; Michelle B van Egmond-Ebbeling; Denise C P van der Linden; Eelco W Hoving; Antoinette Y N Schouten-van Meeteren; Saskia M Imhof Journal: J Neuroophthalmol Date: 2021-10-29 Impact factor: 4.415
Authors: Myrthe A Nuijts; Saskia M Imhof; Nienke Veldhuis; Coco C Dekkers; Antoinette Y N Schouten-van Meeteren; Inge Stegeman Journal: PLoS One Date: 2021-12-23 Impact factor: 3.240